Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Growth Rate of the Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market?

In recent times, there has been noticeable growth in the therapeutics market for castration-resistant prostate cancer (CRPC) and hormone-refractory prostate cancer (HRPCA). This market, which was worth $7.96 billion in 2024, is predicted to grow to $8.43 billion in 2025, with a compound annual growth rate (CAGR) of 5.9%. The growth observed in the past years can be linked to factors such as the increasing occurrence of prostate cancer, the expanded use of androgen deprivation therapy (ADT) which subsequently leads to resistance, the increasing availability of targeted therapy options, enhanced diagnostic imaging capabilities, and increased healthcare investments in oncology infrastructure.

What Growth Rate Is Forecasted for the Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market by 2029?

The therapeutics market size for castration-resistant prostate cancer (crpc) or hormone-refractory prostate cancer (hrpca) is projected to experience notable expansion in the approaching years, anticipating to reach $10.48 billion in 2029 with a compound annual growth rate (CAGR) of 5.6%. The upsurge during the forecast period is expected to be driven by the growing acceptance of precision oncology and biomarker-based therapies, elevated requirement for next-generation hormonal and radioligand therapies, an expanding clinical trials pipeline for advanced prostate cancer, and an increasing pipeline of targeted and immuno-oncology agents. The forecast period is also set to see an increased demand for personalized medicine approaches. Noteworthy trends anticipated during this period comprise the development of combination immunotherapy regimens, the inclusion of genomic profiling in clinical decision-making, the integration of digital health resources for patient monitoring, advancements in bispecific T-cell engagers, and the evolution of tumor microenvironment modulators.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24495&type=smp

Which Key Companies Are Shaping the Future of the Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market?

Major companies operating in the castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics market are Pfizer Inc., Johnson And Johnson, Merck & Co. Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Takeda Pharmaceutical Company Limited, Astellas Pharma Inc., Daiichi Sankyo Co. Ltd., Lantheus Holdings Inc., POINT Biopharma Global Inc., Clovis Oncology Inc., Arvinas Inc., Clarity Pharmaceuticals Ltd, Modra Pharmaceuticals B.V., Oncternal Therapeutics Inc., Zenith Epigenetics Ltd., ESSA Pharma Inc.

Which Factors Are Driving Demand in the Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Industry?

The escalating occurrence of prostate cancer is anticipated to stimulate the expansion of the castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics market. Prostate cancer is a form of cancer that arises in the prostate gland, a tiny gland situated beneath the bladder and in front of the rectum in males. The increasing occurrence of this disease is attributed to the aging population as the likelihood of manifesting prostate cancer escalates notably with age. Castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics play a vital role in the treatment of prostate cancer by targeting progressive stages of the ailment that are no longer responsive to standard hormone therapy. These therapeutic options benefit patients by impeding disease progression and managing symptoms, thereby improving their quality of life. For instance, as per the National Health Service, a department of the UK government, the number of new prostate cancer cases shot up to 54,732 in 2022, depicting a surge of 11,354 cases in comparison to 2021. Consequently, the escalating occurrence of prostate cancer is steering the expansion of the castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=24495&type=smp

How Is the Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market Segmented by Several Divisions?

The castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics market covered in this report is segmented –

1) By Therapy Type: Hormonal Therapy, Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy

2) By Route Of Administration: Oral, Injectable, Intravenous

3) By End User: Hospitals, Oncology Centers, Ambulatory Surgical Centers, Other End Users

Subsegments:

1) By Hormonal Therapy: Androgen Receptor (AR) Inhibitors, Androgen Synthesis Inhibitors, Luteinizing Hormone-Releasing Hormone (LHRH) Agonists Or Antagonists, Gonadotropin-Releasing Hormone (GnRH) Agonists Or Antagonists

2) By Chemotherapy: Taxanes, Platinum-Based Agents, Other Chemotherapies

3) By Immunotherapy: Immune Checkpoint Inhibitors, Cancer Vaccines, Cytokine Therapy, Adoptive Cell Therapy

4) By Targeted Therapy: Poly ADP-Ribose Polymerase (PARP) Inhibitors, Phosphoinositide 3-Kinase (PI3K) Or Protein Kinase B (PI3K) Or Mammalian Target Of Rapamycin (mTOR) Inhibitors, Tyrosine Kinase Inhibitors (TKIs), Deoxyribonucleic Acid Damage Response (DDR) Inhibitors

5) By Radiation Therapy: External Beam Radiation Therapy, Brachytherapy, Radiopharmaceuticals

What are the Emerging Market Trends Driving the Growth of the Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Industry?

Significant players in the castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics market are concentrating their efforts on creating novel products and obtaining necessary approvals. These include dual-action tablets aimed at improving the effectiveness of treatment and patient results. Dual-action tablets are innovative formulas that merge two therapeutic components in one dosage, targeting several pathways in the treatment of castration-resistant prostate cancer (CRPC) simultaneously. An example of this took place in August 2023, when Belgium-based Janssen Pharmaceuticals was granted approval by the U.S. Food and Drug Administration (FDA) for Akeega, a pioneering tablet designed to treat adults suffering from BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC). Akeega, a precision medicine, blends a PARP inhibitor (niraparib) with a CYP17 inhibitor (abiraterone acetate) aimed specifically at patients carrying BRCA mutations. Its use in conjunction with prednisone substantially boosts radiographic progression-free survival (rPFS) compared to traditional hormonal therapy alone.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/castration-resistant-prostate-cancer-crpc-or-hormone-refractory-prostate-cancer-hrpca-therapeutics-global-market-report

Which Regions Are Driving Growth in the Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market?

North America was the largest region in the castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=24495

This Report Delivers Insight On:

1. How big is the castration-resistant prostate cancer (crpc) or hormone-refractory prostate cancer (hrpca) therapeutics market, and how is it changing globally?

2. Who are the major companies in the castration-resistant prostate cancer (crpc) or hormone-refractory prostate cancer (hrpca) therapeutics market, and how are they performing?

3. What are the key opportunities and risks in the castration-resistant prostate cancer (crpc) or hormone-refractory prostate cancer (hrpca) therapeutics market right now?

4. Which products or customer segments are growing the most in the castration-resistant prostate cancer (crpc) or hormone-refractory prostate cancer (hrpca) therapeutics market?

5. What factors are helping or slowing down the growth of the castration-resistant prostate cancer (crpc) or hormone-refractory prostate cancer (hrpca) therapeutics market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model